The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Moores Cancer Center · University of California, San Diego · +18 more institutions
Abstract
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals - the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab - for the treatment of patients with recurrent squamous cell carcinoma of the head and neck (HNSCC) that is refractory to…
Citation impact
- FWCI
- 36.59
- Percentile
- 100%
- References
- 166
Authors
19- EEEzra E.W. CohenCorresponding
Moores Cancer Center, University of California, San Diego
- RBR. Bryan Bell
Cancer Institute (WIA), Providence Portland Medical Center
- CBCarlo Bifulco
Providence Portland Medical Center, Cancer Institute (WIA)
- BBBarbara Burtness
Yale Cancer Center
- MLMaura L. Gillison
The University of Texas MD Anderson Cancer Center
Topics & keywords
- Pembrolizumab
- Medicine
- Nivolumab
- Head and neck squamous-cell carcinoma
- Oncology
- Internal medicine
- Immunotherapy
- Cancer
- Good health and well-being